Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1612346 | 0.95 | TP53 (0.47) | TP53ALDH1A1CYP3A4CYP2C19MAPT | |
| SCHEMBL1611309 | 0.95 | TSHR (0.48) | TP53ALDH1A1CYP3A4CYP2C19MAPT | |
| SCHEMBL1611820 | 0.93 | ALDH1A1 (0.53) | ALDH1A1CYP3A4CYP2C19MAPTSMN1; SMN2 | |
| SCHEMBL1493554 | 0.92 | ALDH1A1 (0.52) | TP53ALDH1A1CYP3A4CYP2C19MAPT | |
| SCHEMBL1611670 | 0.91 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C19MAPTTSHR | |
| SCHEMBL1612063 | 0.91 | ALDH1A1 (0.49) | ALDH1A1CYP3A4MAPTSMN1; SMN2NTRK1 | |
| SCHEMBL1612883 | 0.91 | ALDH1A1 (0.45) | TP53ALDH1A1CYP3A4CYP2C19MAPT | |
| SCHEMBL1493526 | 0.90 | ALDH1A1 (0.49) | ALDH1A1CYP3A4CYP2C19MAPTTSHR | |
| SCHEMBL1610585 | 0.90 | ALDH1A1 (0.52) | ALDH1A1CYP3A4CYP2C19MAPTTSHR | |
| SCHEMBL1493492 | 0.90 | MAPT (0.48) | TP53ALDH1A1CYP3A4CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | claimed |
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2288603-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | TP53 4867/4885ALDH1A1 3233/4885CYP3A4 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.